This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Universal ALD. During the reaction, Universal ALD in the sample or standard competes with a fixed amount of Universal ALD on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Universal ALD. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Universal ALD in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Aldosterone is a steroid hormone synthesized from cholesterol in the adrenal cortex. Aldosterone is metabolized in the kidney and liver, and functions as the key mineralocorticoid in the control of sodium and potassium balance. Synthesis and release of aldosterone by the adrenal gland is primarily regulated by the renin-angiotensinalsdosterone system (RAAS), the main regulatory system involved in blood pressure regulation, renal hemodynamics, and sodium-volume homeostasis. Measurement of serum aldosterone in conjunction with plasma renin is used clinically to differentiate between primary and secondary aldosteronism. Primary aldosteronism (hyperaldoseronism) is characterized by a very low renin: aldosteone ratio leading to the retention of sodium and increased blood pressure, and is typically the result of renal gland hyperplasia or tumors. In secondary aldosteronism, hyperproduction of aldosterone results from external conditions such as heart failure and renal artery disease that reduce renal blood flow and stimulate the RAAS mechanism. The RAAS directly affects vascular and cardiac remodeling through proliferative and inflammatory signaling, as aldosterone and salt have been shown to increase the expression of intracellular cyclooxygenase2, osteopontin, and MCP-1 in rats. Aldosterone acts by binding to the mineralocorticoid receptor (MR) triggering the transcription of hormone responsive genes, and clinical studies have shown that patients with congestive heart failure or after myocardial infarction benefited from MR antagonist treatment. As pharmacological modulation of nuclear hormone receptors is a common strategy for the treatment of cardiovascular disease, determining the effect of such treatments on ab136933 Aldosterone ELISA Kit 2 the RAAS is of increasing value in evaluating the safety and efficacy of new targeted therapeutics